| Pulmonary arterial hypertension

Adempass vs Tadliq

Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.

Deep comparison between: Adempas vs Tadliq with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTadliq has a higher rate of injection site reactions vs Adempas based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tadliq but not Adempas, including UnitedHealthcare

Category

Adempas

Tadliq

At A Glance

RouteOral

FrequencyThree times daily

ClassSoluble guanylate cyclase (sGC) stimulator

RouteOral

FrequencyOnce daily

ClassPDE5 inhibitor

Indications

Chronic thromboembolic pulmonary hypertension
Pulmonary arterial hypertension

Pulmonary arterial hypertension

Dosing

Chronic thromboembolic pulmonary hypertension, Pulmonary arterial hypertension Start at 1 mg three times a day (or 0.5 mg if hypotension risk); increase by 0.5 mg no sooner than every 2 weeks as tolerated, to a maximum of 2.5 mg three times a day.

Pulmonary arterial hypertension 40 mg (10 mL) once daily with or without food; start at 20 mg (5 mL) once daily in mild-to-moderate renal or mild-to-moderate hepatic impairment, increasing to 40 mg based on tolerability; avoid in severe renal impairment and severe hepatic impairment; when initiating TADLIQ in patients on ritonavir for at least one week, start at 20 mg once daily and increase to 40 mg based on tolerability; when starting ritonavir in patients already on TADLIQ, stop TADLIQ at least 24 hours prior and resume at 20 mg once daily after at least one week.

Contraindications

Pregnancy
Concomitant use of nitrates or nitric oxide donors in any form
Concomitant use of PDE-5 inhibitors (sildenafil, tadalafil, or vardenafil) or nonspecific PDE inhibitors (dipyridamole or theophylline)
Concomitant use of other soluble guanylate cyclase (sGC) stimulators
Pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP)

Concomitant use of any form of organic nitrate, either regularly or intermittently
Concomitant use of guanylate cyclase (GC) stimulators such as riociguat
Known serious hypersensitivity to tadalafil (TADLIQ, ADCIRCA, or CIALIS)

Drug Interactions

695View drug interactions

1155View drug interactions

Adverse Reactions

Most common (>=3%) Headache, dyspepsia and gastritis, dizziness, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux disease, constipation

Serious Embryo-fetal toxicity, hypotension, bleeding

Most common (>=9%) Headache, myalgia, nasopharyngitis, flushing, respiratory tract infection, pain in extremity, nausea, back pain, dyspepsia, nasal congestion

Serious Hypotension, visual loss, hearing loss, priapism

Postmarketing Serious cardiovascular events (myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, tachycardia), hypersensitivity reactions (urticaria, Stevens-Johnson syndrome, exfoliative dermatitis), migraine, seizure, transient global amnesia, visual field defect, retinal vein occlusion, retinal artery occlusion, NAION, sudden hearing decrease or loss, priapism

Pharmacology

Riociguat is a soluble guanylate cyclase (sGC) stimulator with a dual mode of action: it sensitizes sGC to endogenous nitric oxide (NO) by stabilizing the NO-sGC binding, and directly stimulates sGC via a separate binding site independently of NO, increasing cGMP generation and leading to vasodilation.

PDE5 inhibitor; tadalafil selectively inhibits phosphodiesterase type 5, increasing cGMP concentrations in pulmonary vascular smooth muscle, resulting in relaxation and vasodilation of the pulmonary vascular bed in patients with pulmonary arterial hypertension.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Adempas